Search
Oxford, UK based OMass Therapeutics announced a $310M series C today, advancing its small molecule platform, including the lead MC2 (melanocortin-2) receptor antagonist that is in phase 1
CEO Ros Deegan describes the raise and the new investors that it brings into the company, and updates us on the company's pipeline progress.
20 hours ago
Oxford, UK based OMass Therapeutics, experts in the use of mass spectrometry in drug development, recently landed a $20M up front licensing deal with Roche on one of its preclinical candidates for IBD
CEO Ros Deegan discusses the deal and the path to getting there, and she highlights some of OMass' other programs the company is driving...
Oct 9, 2025
OMass Therapeutics CEO Ros Deegan on the company's "whole ecosystem" approach to drug discovery
She describes OMass' platform and rare disease focus.
May 1, 2024
.png){kind=logo}